Despite the fact that inflammatory bowel disease (IBD) has still no recognised therapy,
treatments which have proven at least mildly successful in improving IBD symptoms include …

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory condition that is
medicated by genetic, immune, and environmental factors. At least 66 different kinds of …

Butyrate, an intestinal microbiota metabolite of dietary fiber, has been shown to exhibit
protective effects toward inflammatory diseases such as ulcerative colitis (UC) and …

Delivering drugs directly to the inflamed intestinal sites to treat inflammatory bowel disease
(IBD), particularly Crohn's and ulcerative colitis, is highly challenging. Recent advances in …

Inflammatory bowel diseases (IBDs) are chronic disorders of modern society, requiring
management strategies aimed at prolonging an active life and establishing the exact …

Background Microbiota dysbiosis and impaired barrier function are among the most
prominent features of inflammatory bowel disease. In the gastrointestinal tract, hydrogen …

The mucosal immune system mediates contact between the host and the trillions of
microbes that symbiotically colonize the gastrointestinal tract. Failure to tolerate the antigens …

Enzymes with intracellular activity have significant potential to treat diseases. Protein
nanoparticles (NPs) considerably enhance intracellular delivery of enzymes. We have …

For inflammatory bowel disease (IBD) treatment, local delivery of molecules loaded in
nanoparticles to the inflamed colon could be a promising strategy. The aim of this study was …

Receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-
pass transmembrane protein taken in diverse chronic inflammatory conditions. RAGE …